Tracy Bhikram1, Rana Elmaghraby1,2, Elia Abi-Jaoude1,3, Paul Sandor1,2. 1. Department of Psychiatry, University Health Network and University of Toronto, Toronto, ON, Canada. 2. Youthdale Treatment Centre, Toronto, ON, Canada. 3. Department of Psychiatry, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Abstract
Objective: Tourette syndrome (TS) is a neuropsychiatric disorder that is highly associated with several comorbidities. Given the complex and multifaceted nature of TS, the condition is managed by a wide variety of practitioners in different disciplines. The goal of this study was to investigate health service delivery and care practices by clinicians who see TS patients across different geographic settings internationally. Methods: A comprehensive questionnaire was developed to assess clinical care resources for patients with TS and was sent to clinicians in Canada (CA), the United States (US), Europe (EU), and the United Kingdom (UK). Responses were compared quantitatively between geographic regions. Results: The majority of respondents, regardless of region, reported that fewer than 40% of their case-load are patients with tics. The accessibility of TS services varied among regions, as indicated by differences in wait times, telemedicine offerings, comorbidity management and the availability of behavioral therapies. First-line pharmacotherapy preferences varied among physicians in different geographical regions with CA respondents preferring alpha-2-adrenergic agonists and respondents from the UK and EU preferring dopamine receptor antagonists. Discussion: The results suggest that there is a scarcity of specialized TS clinics, potentially making access to services challenging, especially for patients newly diagnosed with TS. Differences in regional pharmacotherapeutic preferences are reflected in various published treatment guidelines in EU and North America. The lack of dedicated specialists and telemedicine availability, coupled with differences in comorbidity management, highlight the need for interprofessional care and holistic management to improve health care delivery to patients with TS.
Objective: Tourette syndrome (TS) is a neuropsychiatric disorder that is highly associated with several comorbidities. Given the complex and multifaceted nature of TS, the condition is managed by a wide variety of practitioners in different disciplines. The goal of this study was to investigate health service delivery and care practices by clinicians who see TS patients across different geographic settings internationally. Methods: A comprehensive questionnaire was developed to assess clinical care resources for patients with TS and was sent to clinicians in Canada (CA), the United States (US), Europe (EU), and the United Kingdom (UK). Responses were compared quantitatively between geographic regions. Results: The majority of respondents, regardless of region, reported that fewer than 40% of their case-load are patients with tics. The accessibility of TS services varied among regions, as indicated by differences in wait times, telemedicine offerings, comorbidity management and the availability of behavioral therapies. First-line pharmacotherapy preferences varied among physicians in different geographical regions with CA respondents preferring alpha-2-adrenergic agonists and respondents from the UK and EU preferring dopamine receptor antagonists. Discussion: The results suggest that there is a scarcity of specialized TS clinics, potentially making access to services challenging, especially for patients newly diagnosed with TS. Differences in regional pharmacotherapeutic preferences are reflected in various published treatment guidelines in EU and North America. The lack of dedicated specialists and telemedicine availability, coupled with differences in comorbidity management, highlight the need for interprofessional care and holistic management to improve health care delivery to patients with TS.
Authors: C M Eddy; R Rizzo; M Gulisano; A Agodi; M Barchitta; P Calì; M M Robertson; A E Cavanna Journal: J Neurol Date: 2010-09-23 Impact factor: 4.849
Authors: Sara Beth Wolicki; Rebecca H Bitsko; Melissa L Danielson; Joseph R Holbrook; Benjamin Zablotsky; John T Walkup; Douglas W Woods; Jonathan W Mink Journal: J Dev Behav Pediatr Date: 2019 Jul/Aug Impact factor: 2.225
Authors: Mark Olfson; Stephen Crystal; Tobias Gerhard; Cecilia Huang; James T Walkup; Lawrence Scahill; John T Walkup Journal: J Am Acad Child Adolesc Psychiatry Date: 2011-02 Impact factor: 8.829
Authors: Tamara Pringsheim; Anthony Lang; Roger Kurlan; Michelle Pearce; Paul Sandor Journal: Dev Med Child Neurol Date: 2008-10-24 Impact factor: 5.449
Authors: Christos Ganos; Harini Sarva; Lille Kurvits; Donald L Gilbert; Andreas Hartmann; Yulia Worbe; Pablo Mir; Kirsten R Müller-Vahl; Alexander Münchau; David Shprecher; Harvey S Singer; Wissam Deeb; Michael S Okun; Irene A Malaty; Mark Hallett; Marina Aj Tijssen; Tamara Pringsheim; Davide Martino Journal: Tremor Other Hyperkinet Mov (N Y) Date: 2021-10-28